Zobrazeno 1 - 10
of 991
pro vyhledávání: '"LEPTOMENINGEAL DISEASE"'
Autor:
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, T. A. Juratli
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-12 (2024)
Abstract Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here,
Externí odkaz:
https://doaj.org/article/0fb644eeacee4ed68b3f90f56d2e1371
Autor:
Julian Steininger, Christoph G Radosa, Matthias Meinhardt, Friedegund Meier, Frank Friedrich Gellrich
Publikováno v:
EJC Skin Cancer, Vol 2, Iss , Pp 100018- (2024)
Externí odkaz:
https://doaj.org/article/e7a5d64e78604126a87c46e9ca58a8ec
Publikováno v:
Drug Delivery, Vol 31, Iss 1 (2024)
Leptomeningeal disease (LMD) refers to the infiltration of cancer cells into the leptomeningeal compartment. Leptomeninges are the two membranous layers, called the arachnoid membrane and pia mater. The diffuse nature of LMD poses a challenge to its
Externí odkaz:
https://doaj.org/article/ace05960f5e4499f8f88ef50f5828ede
Autor:
Niraula, Sujan 1, Gouli, Sugam 2, Baran, AndreaM. 3, O'Regan, Ruth 3, Tyburski, Haley 3, Zhang, Huina 3, Hardy, Sara 4, Mohile, Nimish 3, Anders, Carey K. 5, Dhakal, Ajay 3, ⁎
Publikováno v:
In Clinical Breast Cancer January 2025 25(1):65-74
Autor:
Ugur Sener, Mason Webb, William G. Breen, Bryan J. Neth, Nadia N. Laack, David Routman, Paul D. Brown, Anita Mahajan, Kelsey Frechette, Arkadiusz Z. Dudek, Svetomir N. Markovic, Matthew S. Block, Robert R. McWilliams, Anastasios Dimou, Lisa A. Kottschade, Heather N. Montane, Sani H. Kizilbash, Jian L. Campian
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2024)
Introduction Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic t
Externí odkaz:
https://doaj.org/article/e46cf582bd95407aa5330e020924b4ae
Autor:
Priya U. Kumthekar, Barbara Blouw, Perry Corkos, Seema Nagpal, Arushi Tripathy, David Piccioni, Michael Youssef
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionCNSide is a platform that detects and characterizes tumor cells in the cerebrospinal fluid (CSF) of patients with leptomeningeal disease (LMD). The platform was validated per College of American Pathologists (CAP) and Clinical Laboratorie
Externí odkaz:
https://doaj.org/article/a4602abf11c5492b932f0f10399332db
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despit
Externí odkaz:
https://doaj.org/article/f0834991576d4336a47fe5c576905019
Autor:
Benita Wolf, Vincent Dunet, Estelle Dubruc, Ana Dolcan, Marie Nicod Lalonde, Luis Schiappacasse, Khalil Zaman
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 1425-1435 (2023)
Nervous system metastases (CNSm) are late events associated with poor outcomes in endocrine-sensitive HER2-negative breast cancer (BC) patients, especially in the presence of leptomeningeal disease (LMD). Effective treatments are extremely limited in
Externí odkaz:
https://doaj.org/article/d2e67c7f36e749e8bb3e8f6b17496dd1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kelsey M. Frechette, William G. Breen, Paul D. Brown, Ugur T. Sener, Lauren M. Webb, David M. Routman, Nadia N. Laack, Anita Mahajan, Eric J. Lehrer
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1792 (2024)
Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of th
Externí odkaz:
https://doaj.org/article/bcf4ca29db60462c8c873544ff797fa1